Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.56 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.55 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.45 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2697302 | 0.82 | CYP11B1 (0.50) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL20094967 | 0.80 | FDPS (0.50) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL19004884 | 0.80 | FDPS (0.50) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL19200881 | 0.79 | FDPS (0.49) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL16084711 | 0.78 | FDPS (0.56) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL4682917 | 0.78 | FDPS (0.52) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL3690697 | 0.78 | TBXAS1 (0.64) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL4968502 | 0.78 | FDPS (0.51) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL15397151 | 0.77 | FDPS (0.70) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL18733094 | 0.77 | FDPS (0.47) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002327-A1 | SMALL-MOLECULE REGULATOR OF TLR8 | TSINGHUA UNIVERSITY (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20230002327-A1 | SMALL-MOLECULE REGULATOR OF TLR8 | TSINGHUA UNIVERSITY (CN) | 2023-01-05 | — | — | US | disclosed |
| CN-112174903-B | Small molecule modulators of TLR8 | 清华大学 | 2022-07-12 | — | — | CN | disclosed |
| EP-3998255-A1 | SMALL-MOLECULE REGULATOR OF TLR8 | Tsinghua University (CN) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021000755-A1 | SMALL-MOLECULE REGULATOR OF TLR8 | 清华大学 | 2021-01-07 | — | — | WO | disclosed |
| CN-112174903-A | Small molecule modulators of TLR8 | 清华大学 | 2021-01-05 | — | — | CN | disclosed |
| EP-2029169-A2 | RECOMBINANT VIRAL VACCINE | TRANSGENE S.A. (FR) | 2009-03-04 | — | — | EP | disclosed |
| EP-1902717-A2 | Vasopressin antagonist and oxytocin antagonist | Otsuka Pharmaceutical Company, Limited (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0620003-B1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMA CO LTD (JP) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007147529-A2 | RECOMBINANT VIRAL VACCINE | TRANSGENE S.A. (FR) | 2007-12-27 | — | — | WO | disclosed |
| EP-1000620-B1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-1121933-A1 | Premixed alatrofloxacin injectable compositions | Pfizer Products Inc. (US) | 2001-08-08 | — | — | EP | disclosed |
| US-6166036-A | Lp(a)-lowering agent and apolipoprotein (a) formation suppressing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1000620-A1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-5753644-A | Vasopressin antagonist and oxytocin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5677299-A | VASOPRESSIN OR OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5622947-A | VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| US-5498609-A | Benzoazepinyl compounds as oxytocin and vasopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5145865-A | Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1992-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002327-A1 | SMALL-MOLECULE REGULATOR OF TLR8 | TLR8, TLR6, TLR1 | FDPS 3145/4885GGPS1 2237/4885BTN3A1 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.